积极数据-话题@MedSci

#积极数据#

26篇内容 | 468人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1803245, encodeId=19a0180324552, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=Vaxzevria针对Omicron变体，取得初步积极数据, objectType=article, longId=294094, objectId=c1e6294094e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e6294094e0, replyNumber=0, likeNumber=47, createdTime=2022-02-12, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e6294094e0, moduleTitle=Vaxzevria针对Omicron变体，取得初步积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e6294094e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803246, encodeId=dc07180324648, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, objectType=article, longId=726291, objectId=eddae262914c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eddae262914c, replyNumber=0, likeNumber=49, createdTime=2022-05-19, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eddae262914c, moduleTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eddae262914c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803244, encodeId=65ed180324499, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=干细胞疗法！治疗1型糖尿病取得积极数据, objectType=article, longId=218864, objectId=8453218864cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8453218864cc, replyNumber=0, likeNumber=35, createdTime=2022-01-21, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8453218864cc, moduleTitle=干细胞疗法！治疗1型糖尿病取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8453218864cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803243, encodeId=2625180324373, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=2019年ACR / ARP：COAST-X研究展示了ixekizumab治疗非放射性轴性脊柱关节炎的积极数据, objectType=article, longId=182957, objectId=980118295e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=980118295e5b, replyNumber=0, likeNumber=0, createdTime=2019-12-24, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=980118295e5b, moduleTitle=2019年ACR / ARP：COAST-X研究展示了ixekizumab治疗非放射性轴性脊柱关节炎的积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=980118295e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803241, encodeId=45831803241a3, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=Destiny Pharma：有关XF-73 I期试验的积极数据, objectType=article, longId=159193, objectId=26d71591933c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d71591933c, replyNumber=0, likeNumber=38, createdTime=2019-04-09, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d71591933c, moduleTitle=Destiny Pharma：有关XF-73 I期试验的积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26d71591933c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803242, encodeId=980a180324260, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=蓝鸟生物针对脑性肾上腺皮质营养不良症的慢病毒基因疗法，临床展现出积极数据, objectType=article, longId=180048, objectId=536a1800487c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=536a1800487c, replyNumber=0, likeNumber=46, createdTime=2020-09-08, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=536a1800487c, moduleTitle=蓝鸟生物针对脑性肾上腺皮质营养不良症的慢病毒基因疗法，临床展现出积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=536a1800487c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803240, encodeId=f8d4180324061, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=2018年美国眼科学会年会：GenSight生物技术公司展示GS010的积极数据, objectType=article, longId=150997, objectId=e0e215099e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0e215099e43, replyNumber=0, likeNumber=31, createdTime=2018-11-13, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0e215099e43, moduleTitle=2018年美国眼科学会年会：GenSight生物技术公司展示GS010的积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0e215099e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803239, encodeId=3ed31803239d6, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=Siamab制药宣布ST1抗体治疗卵巢癌的积极数据, objectType=article, longId=145414, objectId=1b6f1454146b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b6f1454146b, replyNumber=0, likeNumber=32, createdTime=2019-02-25, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b6f1454146b, moduleTitle=Siamab制药宣布ST1抗体治疗卵巢癌的积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b6f1454146b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803238, encodeId=110918032388c, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=第一三共公布DS-8201治疗胃癌全新的积极数据, objectType=article, longId=127273, objectId=a98112e273b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a98112e273b0, replyNumber=0, likeNumber=29, createdTime=2018-11-06, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a98112e273b0, moduleTitle=第一三共公布DS-8201治疗胃癌全新的积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a98112e273b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803237, encodeId=8eed180323e22, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=Relypsa高钾血症药物Veltassa® （patiromer）IV期临床斩获积极数据, objectType=article, longId=122658, objectId=1e5f12265855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e5f12265855, replyNumber=0, likeNumber=48, createdTime=2018-10-14, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e5f12265855, moduleTitle=Relypsa高钾血症药物Veltassa® （patiromer）IV期临床斩获积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e5f12265855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803235, encodeId=4b2c1803235f2, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, objectType=article, longId=73839, objectId=0b9ee38391d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9ee38391d, replyNumber=0, likeNumber=41, createdTime=2016-12-17, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9ee38391d, moduleTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9ee38391d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803234, encodeId=769a1803234c1, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=ASCO 2016：PD-1免疫疗法Keytruda多种组合方案治疗晚期黑色素瘤表现积极数据, objectType=article, longId=70123, objectId=6af2e012384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6af2e012384, replyNumber=0, likeNumber=36, createdTime=2017-02-03, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6af2e012384, moduleTitle=ASCO 2016：PD-1免疫疗法Keytruda多种组合方案治疗晚期黑色素瘤表现积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6af2e012384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803236, encodeId=9a25180323668, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, objectType=article, longId=77492, objectId=45e5e749218, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45e5e749218, replyNumber=0, likeNumber=29, createdTime=2017-03-28, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e5e749218, moduleTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e5e749218)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803229, encodeId=fb351803229dc, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=拜耳眼科药物Eylea III期VISTA-DME取得积极数据, objectType=article, longId=30694, objectId=d78b3069424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d78b3069424, replyNumber=0, likeNumber=40, createdTime=2015-01-10, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d78b3069424, moduleTitle=拜耳眼科药物Eylea III期VISTA-DME取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d78b3069424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803233, encodeId=fac11803233b3, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=诺华公布新获批抗癌药Zykadia积极数据, objectType=article, longId=36078, objectId=c72b360e89b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c72b360e89b, replyNumber=0, likeNumber=32, createdTime=2014-08-10, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c72b360e89b, moduleTitle=诺华公布新获批抗癌药Zykadia积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c72b360e89b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803231, encodeId=efc8180323106, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=GSK新复方药Anoro Ellipta 3项III期取得积极数据, objectType=article, longId=31976, objectId=dc24319e6be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc24319e6be, replyNumber=0, likeNumber=34, createdTime=2014-03-19, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc24319e6be, moduleTitle=GSK新复方药Anoro Ellipta 3项III期取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc24319e6be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803230, encodeId=b38a180323021, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=勃林格faldaprevir治疗HCV/HIV合并感染III期取得积极数据, objectType=article, longId=31630, objectId=b140316307c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b140316307c, replyNumber=0, likeNumber=42, createdTime=2014-04-02, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b140316307c, moduleTitle=勃林格faldaprevir治疗HCV/HIV合并感染III期取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b140316307c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803226, encodeId=e36318032265a, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=诺华H7N9流感疫苗I期临床取得积极数据, objectType=article, longId=26816, objectId=ab08268161c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab08268161c, replyNumber=0, likeNumber=53, createdTime=2014-07-15, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab08268161c, moduleTitle=诺华H7N9流感疫苗I期临床取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab08268161c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803227, encodeId=6066180322e57, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=吉利德idelalisib关键性II期iNHL试验取得积极数据, objectType=article, longId=27832, objectId=19052e832dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19052e832dd, replyNumber=0, likeNumber=44, createdTime=2014-03-15, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19052e832dd, moduleTitle=吉利德idelalisib关键性II期iNHL试验取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19052e832dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803232, encodeId=c419180323271, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, objectTitle=uniQue公布基因疗法Glybera 6年随访积极数据, objectType=article, longId=32024, objectId=2bac32024ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bac32024ad, replyNumber=0, likeNumber=34, createdTime=2014-08-17, rootId=0, userName=江川靖瑶, userId=e0752500025, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bac32024ad, moduleTitle=uniQue公布基因疗法Glybera 6年随访积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bac32024ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

积极数据

2020-05-29

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

Vaxzevria针对Omicron变体，取得初步积极数据

2022-02-12

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据

2022-05-19

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

干细胞疗法！治疗1型糖尿病取得积极数据

2022-01-21

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

2019年ACR / ARP：COAST-X研究展示了ixekizumab治疗非放射性轴性脊柱关节炎的积极数据

2019-12-24

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

Destiny Pharma：有关XF-73 I期试验的积极数据

2019-04-09

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

蓝鸟生物针对脑性肾上腺皮质营养不良症的慢病毒基因疗法，临床展现出积极数据

2020-09-08

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

2018年美国眼科学会年会：GenSight生物技术公司展示GS010的积极数据

2018-11-13

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

Siamab制药宣布ST1抗体治疗卵巢癌的积极数据

2019-02-25

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

第一三共公布DS-8201治疗胃癌全新的积极数据

2018-11-06

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

Relypsa高钾血症药物Veltassa® （patiromer）IV期临床斩获积极数据

2018-10-14

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据

2016-12-17

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

ASCO 2016：PD-1免疫疗法Keytruda多种组合方案治疗晚期黑色素瘤表现积极数据

2017-02-03

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据

2017-03-28

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

拜耳眼科药物Eylea III期VISTA-DME取得积极数据

2015-01-10

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

诺华公布新获批抗癌药Zykadia积极数据

2014-08-10

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

GSK新复方药Anoro Ellipta 3项III期取得积极数据

2014-03-19

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

勃林格faldaprevir治疗HCV/HIV合并感染III期取得积极数据

2014-04-02

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

诺华H7N9流感疫苗I期临床取得积极数据

2014-07-15

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

吉利德idelalisib关键性II期iNHL试验取得积极数据

2014-03-15

江川靖瑶 (审核中...)

前往app查看评论内容

#积极数据#

uniQue公布基因疗法Glybera 6年随访积极数据

2014-08-17

科室
- - 订阅+
  - 更多科室
工具
服务